A study examining the genetic profiles of 229 pretreatment specimens from patients with stage II or III rectal cancer reported that KRAS and combined KRAS/TP53 mutations acted as independent biomarkers for a poor response to nCRT [14]. This evidence concerns the gene KRAS and rectal cancer.